November 2025—Quest Diagnostics has launched an advanced pharmacogenomic laboratory test service designed to help providers understand a patient’s genetic response to select drug therapies and help determine appropriate medication and dosing. It uses pharmacogenomic information across a range of medical specialties including psychiatry, neurology, cardiology, oncology, rheumatology, and pain management and in the transplant recipient space.
The offering includes a Quest-delivered report with genotype (diplotye) and predicted phenotypic response alongside vital medication guidance via a link to a personalized report powered by Coriell Life Sciences. Clinicians will also have access to GeneDose Live, Coriell’s clinical decision support tool that health care providers can use to conduct a comprehensive evaluation of a patient’s therapeutic regimen, assessing each medication for genetic and nongenetic risks in the context of other prescribed therapies. The report is based on current, evidence-based gene-drug associations. Quest also offers an option with just the genotype and predicted phenotypic response.
Quest Diagnostics, 800-222-0446